Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion

Summary

This study evaluates the efficacy and safety of Conbercept ophthalmic injection. This is a multi-center, randomized, double-masked, placebo-controlled phase III clinical study. 237 patients with central retinal vein occlusion(CRVO) are expected to be enrolled in the study and randomly assigned into the Conbercept ophthalmic injection treatment group or the control group at a ratio of 2:1.

Timeline

Start

2016-05-24

Primary completion

2020-04-13

Completion

2020-09-28

Drugs

Indications